ALSO READ: Lockdown serves domestic pharma the bitter pill: April growth slips
The trials are currently happening at five centres in England. “Based on strong preclinical data, we are hopeful that once we get the results of Phase-I trials, which will be available in a month, this candidate compound could be moved to the late-stage trials in the form of a vaccine,” said Kukreja.
The UK-based firm has also undertaken two other global research efforts to find a solution to treat Covid-19.
One of them is a Dare-19 trial for Dapagliflozin, which is available as Forxiga in India. Priced at Rs 57 per day, it is used to treat Type 2 diabetes. In a study reported in 2019, in Type 2 diabetes patients, this drug has proven to slow disease progression, particularly related to heart failure and chronic kidney ailment.
“The trial is aimed at testing the effects of the drug (Dapagliflozin) in preventing serious complications such as organ failure in patients, with pre-existing health conditions, a critical goal when treating for Covid-19 virus,” said the company.
has also initiated another study called the Calavi study to evaluate the efficacy and safety of Calquence (acalabrutinib), which is an approved oncology drug. The drug has shown the potential to suppress inflammation because of an overactive immune system.
Hence, the hypothesis is that it can prevent severe Covid-19 when given to patients with mild symptoms. “This drug could suppress inflammation because of an overactive immune system so that the patient does not go from moderate to severe to critical condition,” Kukreja explained.